Malignant tumors and AIDS

G. Nasti, E. Vaccher, D. Errante, U. Tirelli

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

One in six patients with acquired immunodeficiency syndrome (AIDS) both in the USA and Europe develop malignancies, in particular Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL). After an initial rapid increase, the proportion of AIDS patients with KS steadily declined in the USA and in Europe, while the proportion of AIDS-NHL has been stable during the last decade in the USA and Europe. Human immunodeficiency virus (HIV) infected patients are living longer due to advances in antiretroviral therapy and treatment of prophylaxis against opportunistic infections, yet because of their immunodeficiency they are at high risk for cancers, especially NHL. The natural history of cancers in patients with HIV infection differs from that of tile general population. Unusual aspects of tumor localization, growth behaviour and therapeutical response distinguish tumors in patients with HIV infection from those without. The pathologic and virological aspects of HIV-related tumors are peculiar and a pathological classification of HIV-associated systemic lymphomas based on the morphological features of the two main types, ie, blastic and anaplastic cell lymphomas, has been formulated. The treatment of HIV-related neoplasms is controversial as it is not clear whether conventional therapy, particularly chemotherapy, is able to modify the natural history of these malignancies in the HIV setting, Moreover the treatment of HIV-related tumors presents several problems due to the aggressive behaviours of tumors and because of immunosuppressive chemotherapy employed in patients with immunodeficiency. This paper reviews the most relevant data on the epidemiology, pathology and treatment of malignant tumors in patients with HIV infection.

Original languageEnglish
Pages (from-to)243-251
Number of pages9
JournalBiomedicine and Pharmacotherapy
Volume51
Issue number6-7
DOIs
Publication statusPublished - 1997

Fingerprint

Acquired Immunodeficiency Syndrome
HIV
Neoplasms
Virus Diseases
Non-Hodgkin's Lymphoma
Kaposi's Sarcoma
Lymphoma
Therapeutics
Drug Therapy
Opportunistic Infections
Immunosuppressive Agents
Epidemiology
Pathology
Growth
Population

Keywords

  • AIDS
  • Kaposi's sarcoma
  • non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Pharmacology

Cite this

Malignant tumors and AIDS. / Nasti, G.; Vaccher, E.; Errante, D.; Tirelli, U.

In: Biomedicine and Pharmacotherapy, Vol. 51, No. 6-7, 1997, p. 243-251.

Research output: Contribution to journalArticle

Nasti, G. ; Vaccher, E. ; Errante, D. ; Tirelli, U. / Malignant tumors and AIDS. In: Biomedicine and Pharmacotherapy. 1997 ; Vol. 51, No. 6-7. pp. 243-251.
@article{a586c95747de42fb9d26484a2e833f88,
title = "Malignant tumors and AIDS",
abstract = "One in six patients with acquired immunodeficiency syndrome (AIDS) both in the USA and Europe develop malignancies, in particular Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL). After an initial rapid increase, the proportion of AIDS patients with KS steadily declined in the USA and in Europe, while the proportion of AIDS-NHL has been stable during the last decade in the USA and Europe. Human immunodeficiency virus (HIV) infected patients are living longer due to advances in antiretroviral therapy and treatment of prophylaxis against opportunistic infections, yet because of their immunodeficiency they are at high risk for cancers, especially NHL. The natural history of cancers in patients with HIV infection differs from that of tile general population. Unusual aspects of tumor localization, growth behaviour and therapeutical response distinguish tumors in patients with HIV infection from those without. The pathologic and virological aspects of HIV-related tumors are peculiar and a pathological classification of HIV-associated systemic lymphomas based on the morphological features of the two main types, ie, blastic and anaplastic cell lymphomas, has been formulated. The treatment of HIV-related neoplasms is controversial as it is not clear whether conventional therapy, particularly chemotherapy, is able to modify the natural history of these malignancies in the HIV setting, Moreover the treatment of HIV-related tumors presents several problems due to the aggressive behaviours of tumors and because of immunosuppressive chemotherapy employed in patients with immunodeficiency. This paper reviews the most relevant data on the epidemiology, pathology and treatment of malignant tumors in patients with HIV infection.",
keywords = "AIDS, Kaposi's sarcoma, non-Hodgkin's lymphoma",
author = "G. Nasti and E. Vaccher and D. Errante and U. Tirelli",
year = "1997",
doi = "10.1016/S0753-3322(97)83539-1",
language = "English",
volume = "51",
pages = "243--251",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "6-7",

}

TY - JOUR

T1 - Malignant tumors and AIDS

AU - Nasti, G.

AU - Vaccher, E.

AU - Errante, D.

AU - Tirelli, U.

PY - 1997

Y1 - 1997

N2 - One in six patients with acquired immunodeficiency syndrome (AIDS) both in the USA and Europe develop malignancies, in particular Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL). After an initial rapid increase, the proportion of AIDS patients with KS steadily declined in the USA and in Europe, while the proportion of AIDS-NHL has been stable during the last decade in the USA and Europe. Human immunodeficiency virus (HIV) infected patients are living longer due to advances in antiretroviral therapy and treatment of prophylaxis against opportunistic infections, yet because of their immunodeficiency they are at high risk for cancers, especially NHL. The natural history of cancers in patients with HIV infection differs from that of tile general population. Unusual aspects of tumor localization, growth behaviour and therapeutical response distinguish tumors in patients with HIV infection from those without. The pathologic and virological aspects of HIV-related tumors are peculiar and a pathological classification of HIV-associated systemic lymphomas based on the morphological features of the two main types, ie, blastic and anaplastic cell lymphomas, has been formulated. The treatment of HIV-related neoplasms is controversial as it is not clear whether conventional therapy, particularly chemotherapy, is able to modify the natural history of these malignancies in the HIV setting, Moreover the treatment of HIV-related tumors presents several problems due to the aggressive behaviours of tumors and because of immunosuppressive chemotherapy employed in patients with immunodeficiency. This paper reviews the most relevant data on the epidemiology, pathology and treatment of malignant tumors in patients with HIV infection.

AB - One in six patients with acquired immunodeficiency syndrome (AIDS) both in the USA and Europe develop malignancies, in particular Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL). After an initial rapid increase, the proportion of AIDS patients with KS steadily declined in the USA and in Europe, while the proportion of AIDS-NHL has been stable during the last decade in the USA and Europe. Human immunodeficiency virus (HIV) infected patients are living longer due to advances in antiretroviral therapy and treatment of prophylaxis against opportunistic infections, yet because of their immunodeficiency they are at high risk for cancers, especially NHL. The natural history of cancers in patients with HIV infection differs from that of tile general population. Unusual aspects of tumor localization, growth behaviour and therapeutical response distinguish tumors in patients with HIV infection from those without. The pathologic and virological aspects of HIV-related tumors are peculiar and a pathological classification of HIV-associated systemic lymphomas based on the morphological features of the two main types, ie, blastic and anaplastic cell lymphomas, has been formulated. The treatment of HIV-related neoplasms is controversial as it is not clear whether conventional therapy, particularly chemotherapy, is able to modify the natural history of these malignancies in the HIV setting, Moreover the treatment of HIV-related tumors presents several problems due to the aggressive behaviours of tumors and because of immunosuppressive chemotherapy employed in patients with immunodeficiency. This paper reviews the most relevant data on the epidemiology, pathology and treatment of malignant tumors in patients with HIV infection.

KW - AIDS

KW - Kaposi's sarcoma

KW - non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0030787423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030787423&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(97)83539-1

DO - 10.1016/S0753-3322(97)83539-1

M3 - Article

C2 - 9309244

AN - SCOPUS:0030787423

VL - 51

SP - 243

EP - 251

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 6-7

ER -